Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: Implications for transthyretin amyloidosis

Biochemistry

Volumn 44, Issue 25, 2005, Pages 9265-9274

  Wiseman, R Luke ^a   Green, Nora S ^a,b   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b RANDOLPH MACON COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLOMERATION; ASSAYS; DISEASES; DISSOCIATION; OLIGOMERS; PHYSIOLOGY; REACTION KINETICS;

BINDING AFFINITY; HOMOTETRAMERS; NEURODEGENERATION; TRANSTHYRETIN (TTR);

PROTEINS;

OLIGOMER; PREALBUMIN; PROTEIN SUBUNIT; UREA;

AMYLOIDOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; KINETICS; MICROENVIRONMENT; NERVE DEGENERATION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL;

AMYLOIDOSIS; KINETICS; MOLECULAR STRUCTURE; PREALBUMIN; PROTEIN BINDING; PROTEIN DENATURATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN SUBUNITS; THERMODYNAMICS;

EID: 21744452155     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi050352o     Document Type: Article

References (38)

1. Hamilton, J. A., and Benson, M. D. (2001) Transthyretin: a review from a structural perspective, Cell Mol. Life Sci. 58, 1491-1521.
2. Westermark, P., Sletten, K., Johansson, B., and Cornwell, G. G., 3rd. (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci., U.S.A. 87, 2843-2845.
3. Hammarstrom, P., Sekijima, Y., White, J. T., Wiseman, R. L., Lim, A., Costello, C. E., Altland, K., Garzuly, F., Budka, H., and Kelly, J. W. (2003) D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 42, 6656-6663.
4. Plante-Bordeneuve, V., Lalu, T., Misrahi, M., Reilly, M. M., Adams, D., Lacroix, C., and Said, G. (1998) Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy, Neurology 51, 708-714.
5. Jacobson, D. R., McFarlin, D. E., Kane, I., and Buxbaum, J. N. (1992) Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement, Hum. Genet. 89, 353-356.
6. Sekijima, Y., Wiseman, R. L., Matteson, J., Hammarstrom, P., Miller, S. R., Sawkar, A. R., Balch, W. E., and Kelly, J. W. (2005) The Biological and Chemical Basis for Tissue Selective Amyloid Disease, Cell 121, 73-85.
7. Saraiva, M. J. (1995) Transthyretin mutations in health and disease, Hum. Mutat. 5, 191-196.
8. Holmgren, G., Ericzon, B. G., Groth, C. G., Steen, L., Suhr, O., Andersen, O., Wallin, B. G., Seymour, A., Richardson, S., Hawkins, P. N., et al. (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis, Lancet 341, 1113-1116.
9. Suhr, O. B., Ericzon, B. G., and Friman, S. (2002) Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type), Liver Transpl. 8, 787-794.
10. Ando, Y., Tanaka, Y., Nakazato, M., Ericzon, B. G., Yamashita, T., Tashima, K., Sakashita, N., Suga, M., Uchino, M., and Ando, M. (1995) Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation, Biochem. Biophys. Res. Commun. 211, 354-358.
11. Hammarstrom, P., Jiang, X., Hurshman, A. R., Powers, E. T., and Kelly, J. W. (2002) Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity, Proc. Natl. Acad. Sci., U.S.A. 99, 16427-16432.
12. Colon, W., and Kelly, J. W. (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro, Biochemistry 31, 8654-8660.
13. Lai, Z., Colon, W., and Kelly, J. W. (1996) The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid, Biochemistry 35, 6470-6482.
14. Coelho, T., Carvalho, M., Saraiva, M. J., et al. (1993) A Strikingly Benign Evolution of FAP in an Individual Compound Heterozygote for Two TTR Mutations: TTR Met30 and TTR Met119, J. Rheumatol. 20, 179.
15. Hammarstrom, P., Schneider, F., and Kelly, J. W. (2001) Transsuppression of misfolding in an amyloid disease. Science 293, 2459-2462.
16. Hammarstrom, P., Wiseman, R. L., Powers, E. T., and Kelly, J. W. (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics, Science 299, 713-716.
17. Green, N. S., Palaninathan, S. K., Sacchettini, J. C., and Kelly, J. W. (2003) Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization, J. Am. Chem. Soc. 125, 13404-13414.
18. Adamski-Werner, S. L., Palaninathan, S. K., Sacchettini, J. C., and Kelly, J. W. (2004) Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis, J. Med. Chem. 47, 355-374.
19. Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., Kelly, J. W., and Sacchettini, J. C. (2000) Rational design of potent human transthyretin amyloid disease inhibitors, Nat. Struct. Biol. 7, 312-321.
20. Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., and Kelly, J. W. (1996) Inhibiting transthyretin amyloid fibril formation via protein stabilization, Proc. Natl. Acad. Sci., U.S.A. 93, 15051-15056.
21. Oza, V. B., Smith, C., Raman, P., Koepf, E. K., Lashuel, H. A., Petrassi, H. M., Chiang, K. P., Powers, E. T., Sachettinni, J., and Kelly, J. W. (2002) Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors, J. Med. Chem. 45, 321-332.
22. Purkey, H. E., Palaninathan, S. K., Kent, K. C., Smith, C., Safe, S. H., Sacchettini, J. C., and Kelly, J. W. (2004) Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity, Chem. Biol. 11, 1719-1728.
23. Razavi, H., Palaninathan, S. K., Powers, E. T., Wiseman, R. L., Purkey, H. E., Mohamedmohaideen, N. N., Deechongkit, S., Chiang, K. P., Dendle, M. T., Sacchettini, J. C., and Kelly, J. W. (2003) Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action, Angew. Chem., Int. Ed. 42, 2758-2761.
24. Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W., and Buxbaum, J. N. (2004) Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture, Proc. Natl. Acad. Sci., U.S.A. 101, 2817-2822.
25. Sousa, M. M., Cardoso, I., Fernandes, R., Guimaraes, A., and Saraiva, M. J. (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates, Am. J. Pathol. 159, 1993-2000.
26. Lashuel, H. A., Lai, Z., and Kelly, J. W. (1998) Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation, Biochemistry 37, 17851-17864.
27. Damas, A. M., and Saraiva, M. J. (2000) Review: TTR amyloidosis- structural features leading to protein aggregation and their implications on therapeutic strategies, J. Struct. Biol. 130, 290-299.
28. Schneider, F., Hammarstrom, P., and Kelly, J. W. (2001) Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins, Protein Sci. 10, 1606-1613.
29. Lashuel, H. A., Wurth, C., Woo, L., and Kelly, J. W. (1999) The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions, Biochemistry 38, 13560-13573.
30. Fersht, A. (1999) Structure and Mechanism in Protein Science, W. H. Freeman and Company, New York.
31. Foss, T. R., Kelker, M. S., Wiseman, R. L., Wilson, I. A., and Kelly, J. W. (2005) Kinetic Stabilization of the Native State by Protein Engineering: Implications of Transthyretin Amyloidogenesis, J. Mol. Biol. 347, 841-854.
32. Wiseman, R. L., Johnson, S. J., Kelker, M. S., Foss, T., Wilson, I. A., and Kelly, J, W. (2005) Kinetic Stabilization of an Oligomeric Protein by a Single Ligand Binding Event, J. Am. Chem. Soc. 127, 5540-5551.
33. Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., and Kelly, J. W. (1998) Inhibiting transthyretin conformational changes that lead to amyloid fibril formation, Proc. Natl. Acad. Sci., U.S.A. 95, 12956-12960.
34. Leavitt, S., and Freire, E. (2001) Direct measurement of protein binding energetics by isothermal titration calorimetry, Curr. Opin. Struct. Biol. 11, 560-566.
35. McCammon, M. G., Scott, D. J., Keetch, C. A., Greene, L. H., Purkey, H. E., Petrassi, H. M., Kelly, J. W., and Robinson, C. V. (2002) Screening transthyretin amyloid fibril inhibitors: characterization of novel multiprotein, multiligand complexes by mass spectrometry, Structure 10, 851-863.
36. Sacchettini, J. C., and Kelly, J. W. (2002) Therapeutic strategies for human amyloid diseases, Nat. Rev. Drug Discovery 1, 267-275.
37. Bruijn, L. I., Miller, T. M., and Cleveland, D. W. (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS, Annu. Rev. Neurosci. 27, 723-749.
38. Li, S. H., and Li, X. J. (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease, Trends Genet. 20, 146-154.